Last reviewed · How we verify
PMK-S005 1
PMK-S005 1 is a Small molecule drug developed by PharmaKing. It is currently in Phase 2 development.
At a glance
| Generic name | PMK-S005 1 |
|---|---|
| Sponsor | PharmaKing |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PMK-S005 1 CI brief — competitive landscape report
- PMK-S005 1 updates RSS · CI watch RSS
- PharmaKing portfolio CI
Frequently asked questions about PMK-S005 1
What is PMK-S005 1?
PMK-S005 1 is a Small molecule drug developed by PharmaKing.
Who makes PMK-S005 1?
PMK-S005 1 is developed by PharmaKing (see full PharmaKing pipeline at /company/pharmaking).
What development phase is PMK-S005 1 in?
PMK-S005 1 is in Phase 2.
Related
- Manufacturer: PharmaKing — full pipeline
- Compare: PMK-S005 1 vs similar drugs
- Pricing: PMK-S005 1 cost, discount & access